295 related articles for article (PubMed ID: 25392452)
21. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
Mayerhofer M; Aichberger KJ; Florian S; Krauth MT; Hauswirth AW; Derdak S; Sperr WR; Esterbauer H; Wagner O; Marosi C; Pickl WF; Deininger M; Weisberg E; Druker BJ; Griffin JD; Sillaber C; Valent P
FASEB J; 2005 Jun; 19(8):960-2. PubMed ID: 15784722
[TBL] [Abstract][Full Text] [Related]
22. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.
Yang HS; Jansen AP; Komar AA; Zheng X; Merrick WC; Costes S; Lockett SJ; Sonenberg N; Colburn NH
Mol Cell Biol; 2003 Jan; 23(1):26-37. PubMed ID: 12482958
[TBL] [Abstract][Full Text] [Related]
23. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
[TBL] [Abstract][Full Text] [Related]
24. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y
Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089
[TBL] [Abstract][Full Text] [Related]
25. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
[TBL] [Abstract][Full Text] [Related]
26. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
[TBL] [Abstract][Full Text] [Related]
27. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
28. Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
Vakana E; Arslan AD; Szilard A; Altman JK; Platanias LC
PLoS One; 2013; 8(11):e78780. PubMed ID: 24260131
[TBL] [Abstract][Full Text] [Related]
29. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract][Full Text] [Related]
30. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
31. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Mancini M; Petta S; Martinelli G; Barbieri E; Santucci MA
J Cell Biochem; 2010 Feb; 109(2):320-8. PubMed ID: 20014066
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
33. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
34. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
35. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
36. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
38. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
39. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
40. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]